Premium
Probing an Allosteric Pocket of CDK2 with Small Molecules
Author(s) -
Christodoulou Michael S.,
Caporuscio Fabiana,
Restelli Valentina,
Carlino Luca,
Cannazza Giuseppe,
Costanzi Elisa,
Citti Cinzia,
Lo Presti Leonardo,
Pisani Pasquale,
Battistutta Roberto,
Broggini Massimo,
Passarella Daniele,
Rastelli Giulio
Publication year - 2017
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201600474
Subject(s) - allosteric regulation , chemistry , small molecule , stereochemistry , mutagenesis , cyclin dependent kinase , structure–activity relationship , allosteric enzyme , biochemistry , enzyme , cell cycle , mutation , cell , in vitro , gene
The availability of well‐characterized allosteric modulators is crucial for investigating the allosteric regulation of protein function. In a recently identified inactive conformation of cyclin‐dependent kinase 2 (CDK2), an open allosteric pocket was detected and proposed as a site to accommodate allosteric inhibitors. Previous structure‐based approaches allowed the identification of a hit compound expected to bind to this pocket. Herein we report the characterization of this compound by X‐ray crystallography, which surprisingly provided a chemical structure different from that previously reported. Therefore, the compound was synthesized and completely characterized. X‐ray structures of the synthesized and purchased compounds were found to be superimposable. A reaction mechanism was proposed to explain the formation of the structure indicated by crystallography. Moreover, a stereoselective synthesis was developed to evaluate the biological activity of the pure stereoisomers. Modeling studies were performed to unveil the details of the interaction with CDK2. The activity of the obtained compounds was evaluated with various biological assays. Mutagenesis experiments confirmed binding to the allosteric pocket. Finally, the allosteric ligands were shown to inhibit the growth of lung (A549) and ovarian (SKOV3) cancer cell lines. Therefore, this report presents a thorough chemical and biological characterization of the first small‐molecule ligands to be used as probes to study the allosteric modulation of CDK2 activity.